ESMO 24: Bayer Prostate Drugs Old And New Deliver On Survival

The German group's goal of expanding Nubeqa into wider prostate cancer patient populations has probably been reached with the results from the Phase III ARANOTE study, while a combination of its older product Xofigo and Pfizer and Astellas’ Xtandi is set to become standard of care for another subset.